Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 180-190

  Toulany, Mahmoud ^a   Rodemann, H Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

DNA repair; DNA PKcs; Ionizing radiation; NHEJ; PI3K Akt; Radiotherapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFURESERTIB; BORTEZOMIB; CAPECITABINE; CISPLATIN; DALOTUZUMAB; DEXAMETHASONE; ERLOTINIB; ETOPOSIDE; NELFINAVIR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TEMOZOLOMIDE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLON CANCER; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CODE; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; POINT MUTATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DNA END JOINING REPAIR; METABOLISM; NEOPLASMS; RADIATION RESPONSE; RADIATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; DNA DAMAGE; DNA END-JOINING REPAIR; DNA REPAIR; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84948716716     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.07.003     Document Type: Review

References (213)

1. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11:239-253.
2. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 2006, 6:876-885.
3. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6:2166-2174.
4. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62:7350-7356.
5. Krause M., Zips D., Thames H.D., Kummermehr J., Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother. Oncol. 2006, 80:112-122.
6. Nakamura J.L. The epidermal growth factor receptor in malignant gliomas: Pathogenesis and therapeutic implications. Expert Opin. Ther. Targets 2007, 11:463-472.
7. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7:493-507.
8. Traynor A.M., Weigel T.L., Oettel K.R., Yang D.T., Zhang C., Kim K., et al. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer 2013, 81:138-141.
9. Rodemann H.P., Dittmann K., Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int. J. Radiat. Biol. 2007, 83:781-791.
10. Rodemann H.P., Blaese M.A. Responses of normal cells to ionizing radiation. Semin. Radiat. Oncol. 2007, 17:81-88.
11. Toulany M., Rodemann H.P. Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nuklearmedizin 2010, 49(Suppl 1):S26-S30.
12. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
13. Liu Z., Roberts T.M. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006, 5:675-677.
14. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
15. Santi S.A., Lee H. The Akt isoforms are present at distinct subcellular locations. Am. J. Physiol. Cell Physiol. 2010, 298:C580-C591.
16. Viniegra J.G., Martinez N., Modirassari P., Hernandez Losa J., Parada Cobo C., Sanchez-Arevalo Lobo V.J., et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 2005, 280:4029-4036.
17. Feng J., Park J., Cron P., Hess D., Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 2004, 279:41189-41196.
18. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3207-3212.
19. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
20. Cengel K.A., Voong K.R., Chandrasekaran S., Maggiorella L., Brunner T.B., Stanbridge E., et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007, 9:341-348.
21. McKenna W.G., Muschel R.J., Gupta A.K., Hahn S.M., Bernhard E.J. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003, 22:5866-5875.
22. Sekhar K.R., Reddy Y.T., Reddy P.N., Crooks P.A., Venkateswaran A., McDonald W.H., et al. The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. Clin. Cancer Res. 2011, 17:6490-6499.
23. Kao G.D., Jiang Z., Fernandes A.M., Gupta A.K., Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem. 2007, 282:21206-21212.
24. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
25. Garrido-Laguna I., Hong D.S., Janku F., Nguyen L.M., Falchook G.S., Fu S., et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: Outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 2012, 7:e38033.
26. Cheung M., Testa J.R. Diverse mechanisms of AKT pathway activation in human malignancy. Curr. Cancer Drug Targets 2013, 13:234-244.
27. Murthy S.S., Tosolini A., Taguchi T., Testa J.R. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet. Cell Genet. 2000, 88:38-40.
28. Santi S.A., Douglas A.C., Lee H. The Akt isoforms, their unique functions and potential as anticancer therapeutic targets. Biomol. Concepts 2010, 1:389-401.
29. Dummler B., Hemmings B.A. Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 2007, 35:231-235.
30. Cho H., Thorvaldsen J.L., Chu Q., Feng F., Birnbaum M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001, 276:38349-38352.
31. LaRocca J., Pietruska J., Hixon M. Akt1 is essential for postnatal mammary gland development, function, and the expression of Btn1a1. PLoS One 2011, 6:e24432.
32. Fischer-Posovszky P., Tews D., Horenburg S., Debatin K.M., Wabitsch M. Differential function of Akt1 and Akt2 in human adipocytes. Mol. Cell Endocrinol. 2012, 358:135-143.
33. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292:1728-1731.
34. Easton R.M., Cho H., Roovers K., Shineman D.W., Mizrahi M., Forman M.S., et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell Biol. 2005, 25:1869-1878.
35. Manning B.D., Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129:1261-1274.
36. Bellacosa A., Kumar C.C., Di Cristofano A., Testa J.R. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv. Cancer Res. 2005, 94:29-86.
37. Gupta A.K., McKenna W.G., Weber C.N., Feldman M.D., Goldsmith J.D., Mick R., et al. Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin. Cancer Res. 2002, 8:885-892.
38. Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br. J. Cancer 2006, 94:1678-1682.
39. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
40. Hatanpaa K.J., Burma S., Zhao D., Habib A.A. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684.
41. Mukherjee B., McEllin B., Camacho C.V., Tomimatsu N., Sirasanagandala S., Nannepaga S., et al. EGFRvIII and DNA double-strand break repair: A molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009, 69:4252-4259.
42. Li B., Yuan M., Kim I.A., Chang C.M., Bernhard E.J., Shu H.K. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004, 23:4594-4602.
43. Toulany M., Baumann M., Rodemann H.P. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol. Cancer Res. 2007, 5:863-872.
44. Toulany M., Schickfluss T.A., Eicheler W., Kehlbach R., Schittek B., Rodemann H.P. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011, 13:R28.
45. Kim I.A., Bae S.S., Fernandes A., Wu J., Muschel R.J., McKenna W.G., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 2005, 65:7902-7910.
46. Minjgee M., Toulany M., Kehlbach R., Giehl K., Rodemann H.P. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81:1506-1514.
47. Toulany M., Dittmann K., Kruger M., Baumann M., Rodemann H.P. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother. Oncol. 2005, 76:143-150.
48. Leslie N.R., Downes C.P. PTEN function: How normal cells control it and tumour cells lose it. Biochem. J. 2004, 382:1-11.
49. Bassi C., Ho J., Srikumar T., Dowling R.J., Gorrini C., Miller S.J., et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-399.
50. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of PTEN. J. Cell Sci. 2008, 121:249-253.
51. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
52. Sadeq V., Isar N., Manoochehr T. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med. Oncol. 2011, 28:420-423.
53. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158:2097-2106.
54. Bettstetter M., Berezowska S., Keller G., Walch A., Feuchtinger A., Slotta-Huspenina J., et al. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: Loss of PTEN is associated with worse clinical outcome. Hum. Pathol. 2012, 44:829-836.
55. Davis W.J., Lehmann P.Z., Li W. Nuclear PI3K signaling in cell growth and tumorigenesis. Front. Cell Dev. Biol. 2015, 3:24.
56. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A.J., Skele K.L., Hoffman J.P., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell Biochem. 2002, 87:470-476.
57. Lim J., Kim J.H., Paeng J.Y., Kim M.J., Hong S.D., Lee J.I., et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J. Clin. Pathol. 2005, 58:1199-1205.
58. Dobashi Y., Kimura M., Matsubara H., Endo S., Inazawa J., Ooi A. Molecular alterations in AKT and its protein activation in human lung carcinomas. Hum. Pathol. 2012, 43:2229-2240.
59. Ringel M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001, 61:6105-6111.
60. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:5034-5037.
61. Kirkegaard T., Witton C.J., Edwards J., Nielsen K.V., Jensen L.B., Campbell F.M., et al. Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 2010, 56:203-211.
62. Cohen Y., Shalmon B., Korach J., Barshack I., Fridman E., Rechavi G. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol. Oncol. 2010, 116:88-91.
63. Askham J.M., Platt F., Chambers P.A., Snowden H., Taylor C.F., Knowles M.A. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010, 29:150-155.
64. Malanga D., Scrima M., De Marco C., Fabiani F., De Rosa N., De Gisi S., et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008, 7:665-669.
65. Bleeker F.E., Felicioni L., Buttitta F., Lamba S., Cardone L., Rodolfo M., et al. AKT1(E17K) in human solid tumours. Oncogene 2008, 27:5648-5650.
66. Hill M.M., Hemmings B.A. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol. Ther. 2002, 93:243-251.
67. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3636-3641.
68. Ottenhof N.A., de Wilde R.F., Maitra A., Hruban R.H., Offerhaus G.J. Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol. Res. Int. 2011, 2011:620601.
69. Xu X., Sakon M., Nagano H., Hiraoka N., Yamamoto H., Hayashi N., et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol. Rep. 2004, 11:25-32.
70. Nakayama K., Nakayama N., Kurman R.J., Cope L., Pohl G., Samuels Y., et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 2006, 5:779-785.
71. Bacus S.S., Altomare D.A., Lyass L., Chin D.M., Farrell M.P., Gurova K., et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002, 21:3532-3540.
72. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9267-9271.
73. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer. 1995, 64:280-285.
74. Liu A.X., Testa J.R., Hamilton T.C., Jove R., Nicosia S.V., Cheng J.Q. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 1998, 58:2973-2977.
75. Soung Y.H., Lee J.W., Nam S.W., Lee J.Y., Yoo N.J., Lee S.H. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006, 70:285-289.
76. Gonzalez E., McGraw T.E. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7004-7009.
77. Rashmi R., DeSelm C., Helms C., Bowcock A., Rogers B.E., Rader J., et al. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One 2014, 9:e92948.
78. Makinoshima H., Takita M., Saruwatari K., Umemura S., Obata Y., Ishii G., et al. Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. J. Biol. Chem. 2015, 290:17495-17504.
79. Hudson C.D., Hagemann T., Mather S.J., Avril N. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis. 2014, 5:e1160.
80. Santi S.A., Lee H. Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS One 2011, 6:e14614.
81. Cristiano B.E., Chan J.C., Hannan K.M., Lundie N.A., Marmy-Conus N.J., Campbell I.G., et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res. 2006, 66:11718-11725.
82. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999, 274:21528-21532.
83. Turner K.M., Sun Y., Ji P., Granberg K.J., Bernard B., Hu L., et al. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:3421-3426.
84. Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64:7002-7010.
85. Davies M.A., Stemke-Hale K., Tellez C., Calderone T.L., Deng W., Prieto V.G., et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 2008, 99:1265-1268.
86. Masure S., Haefner B., Wesselink J.J., Hoefnagel E., Mortier E., Verhasselt P., et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur. J. Biochem. 1999, 265:353-360.
87. Madhunapantula S.V., Sharma A., Robertson G.P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007, 67:3626-3636.
88. Risso G., Blaustein M., Pozzi B., Mammi P., Srebrow A. Akt/PKB: One kinase, many modifications. Biochem. J. 2015, 468:203-214.
89. Chan C.H., Jo U., Kohrman A., Rezaeian A.H., Chou P.C., Logothetis C., et al. Posttranslational regulation of Akt in human cancer. Cell Biosci. 2014, 4:59.
90. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
91. Winograd-Katz S.E., Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006, 25:7381-7390.
92. Nijkamp M.M., Hoogsteen I.J., Span P.N., Takes R.P., Lok J., Rijken P.F., et al. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiother. Oncol. 2011, 101:165-170.
93. Gazdar A.F., Minna J.D. Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops. Cancer Prev. Res. (Phila.) 2008, 1:156-160.
94. Gazdar A.F., Minna J.D. Inhibition of EGFR signaling: All mutations are not created equal. PLoS Med. 2005, 2:e377.
95. Kasten-Pisula U., Saker J., Eicheler W., Krause M., Yaromina A., Meyer-Staeckling S., et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:1181-1188.
96. Sheridan M.T., O'Dwyer T., Seymour C.B., Mothersill C.E. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. 1997, 5:180-186.
97. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Kehlbach R., Rodemann H.P. Nuclear epidermal growth factor receptor modulates cellular radio-sensitivity by regulation of chromatin access. Radiother. Oncol. 2011, 99:317-322.
98. Huber S.M., Misovic M., Mayer C., Rodemann H.P., Dittmann K. EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother. Oncol. 2012, 103:373-379.
99. Toulany M., Dittmann K., Baumann M., Rodemann H.P. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother. Oncol. 2005, 74:117-129.
100. Zhang T., Cui G.B., Zhang J., Zhang F., Zhou Y.A., Jiang T., et al. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol. Rep. 2010, 24:1683-1689.
101. Valerie K., Yacoub A., Hagan M.P., Curiel D.T., Fisher P.B., Grant S., et al. Radiation-induced cell signaling: Inside-out and outside-in. Mol. Cancer Ther. 2007, 6:789-801.
102. Toulany M., Minjgee M., Kehlbach R., Chen J., Baumann M., Rodemann H.P. ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiother. Oncol. 2010, 97:338-345.
103. Li H.F., Kim J.S., Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat. Oncol. 2009, 4:43.
104. Bussink J., van der Kogel A.J., Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9:288-296.
105. Zhan M., Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol. Histopathol. 2004, 19:915-923.
106. Price B.D., Youmell M.B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996, 56:246-250.
107. Liu Y., Cui B., Qiao Y., Zhang Y., Tian Y., Jiang J., et al. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo. Int. J. Gynecol. Cancer 2011, 21:100-105.
108. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61:3986-3997.
109. Prevo R., Deutsch E., Sampson O., Diplexcito J., Cengel K., Harper J., et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 2008, 68:5915-5923.
110. Fuhrman C.B., Kilgore J., LaCoursiere Y.D., Lee C.M., Milash B.A., Soisson A.P., et al. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol. Oncol. 2008, 110:93-98.
111. Choi E.J., Ryu Y.K., Kim S.Y., Wu H.G., Kim J.S., Kim I.H., et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: Implication in radiation response. Mol. Cancer Res. 2010, 8:1027-1036.
112. Lee C.M., Fuhrman C.B., Planelles V., Peltier M.R., Gaffney D.K., Soisson A.P., et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res. 2006, 12:250-256.
113. Tanno S., Yanagawa N., Habiro A., Koizumi K., Nakano Y., Osanai M., et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res. 2004, 64:3486-3490.
114. Kumar A., Fernandez-Capetillo O., Carrera A.C. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7491-7496.
115. Liu Z., Zhu G., Getzenberg R.H., Veltri R.W. The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J. Cell Biochem. 2015, 116:1341-1349.
116. Nakashio A., Fujita N., Rokudai S., Sato S., Tsuruo T. Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 2000, 60:5303-5309.
117. Lin Y.H., Chen B.Y., Lai W.T., Wu S.F., Guh J.H., Cheng A.L., et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch. Pharmacol. 2015, 388:19-31.
118. Guo S., Lopez-Marquez H., Fan K.C., Choy E., Cote G., Harmon D., et al. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One 2014, 9:e93996.
119. Molife L.R., Yan L., Vitfell-Rasmussen J., Zernhelt A.M., Sullivan D.M., Cassier P.A., et al. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J. Hematol. Oncol. 2014, 7:1.
120. Hyman D.M., Snyder A.E., Carvajal R.D., Gerecitano J.F., Voss M.H., Ho A.L., et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2015, 75:747-755.
121. Lazaridis G., Lambaki S., Karayannopoulou G., Eleftheraki A.G., Papaspirou I., Bobos M., et al. Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther. Onkol. 2014, 190:636-638. (640-5).
122. Bostner J., Karlsson E., Pandiyan M.J., Westman H., Skoog L., Fornander T., et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res. Treat. 2013, 137:397-406.
123. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
124. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002, 21:5673-5683.
125. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003, 17:1794-1805.
126. Choi S.Y., Kim M.J., Kang C.M., Bae S., Cho C.K., Soh J.W., et al. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J. Biol. Chem. 2006, 281:7049-7059.
127. Gardai S.J., Hildeman D.A., Frankel S.K., Whitlock B.B., Frasch S.C., Borregaard N., et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 2004, 279:21085-21095.
128. Toulany M., Kehlbach R., Florczak U., Sak A., Wang S., Chen J., et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol. Cancer Ther. 2008, 7:1772-1781.
129. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008, 22:436-448.
130. Ettl T., Viale-Bouroncle S., Hautmann M.G., Gosau M., Kolbl O., Reichert T.E., et al. AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines. Oral Oncol. 2015, 51:158-163.
131. Zhang S., Zheng X., Huang H., Wu K., Wang B., Chen X., et al. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget 2015, 6:5832-5845.
132. Yu L., Shang Z.F., Hsu F.M., Zhang Z., Tumati V., Lin Y.F., et al. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor. Oncotarget 2015, 6:3848-3860.
133. Chang L., Graham P.H., Hao J., Ni J., Bucci J., Cozzi P.J., et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 2014, 5:e1437.
134. Hein A.L., Ouellette M.M., Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). Int. J. Oncol. 2014, 45:1813-1819.
135. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8:545-554.
136. Chang L., Graham P.H., Hao J., Ni J., Bucci J., Cozzi P.J., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013, 4:e875.
137. Zhan J.F., Wu L.P., Chen L.H., Yuan Y.W., Xie G.Z., Sun A.M., et al. Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation. Cell Oncol. (Dordr.) 2011, 34:451-456.
138. Sahlberg S.H., Spiegelberg D., Glimelius B., Stenerlow B., Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One 2014, 9:e94621.
139. Desai A., Webb B., Gerson S.L. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother. Oncol. 2014, 110:538-545.
140. Piao L.S., Hur W., Kim T.K., Hong S.W., Kim S.W., Choi J.E., et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012, 315:129-137.
141. Zhang M., Atkinson R.L., Rosen J.M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3522-3527.
142. Lin Y., Yang Y., Li W., Chen Q., Li J., Pan X., et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol. Cell. 2012, 48:627-640.
143. Singh S., Trevino J., Bora-Singhal N., Coppola D., Haura E., Altiok S., et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol. Cancer 2012, 11:73.
144. Mehta M., Khan A., Danish S., Haffty B.G., Sabaawy H.E. Radiosensitization of primary human glioblastoma stem-like cells with low-dose AKT inhibition. Mol. Cancer Ther. 2015, 14:1171-1180.
145. Mihatsch J., Toulany M., Bareiss P.M., Grimm S., Lengerke C., Kehlbach R., et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother. Oncol. 2011, 99:300-306.
146. Kang K.B., Zhu C., Wong Y.L., Gao Q., Ty A., Wong M.C. Gefitinib radiosensitizes stem-like glioma cells: Inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83:e43-e52.
147. Apel A., Herr I., Schwarz H., Rodemann H.P., Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008, 68:1485-1494.
148. Rouschop K.M., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest. 2010, 120:127-141.
149. Chaachouay H., Ohneseit P., Toulany M., Kehlbach R., Multhoff G., Rodemann H.P. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother. Oncol. 2011, 99:287-292.
150. Sotelo J., Briceno E., Lopez-Gonzalez M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2006, 144:337-343.
151. Kim K.W., Myers C.J., Jung D.K., Lu B. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer 2014, 5:293-302.
152. Fujiwara K., Iwado E., Mills G.B., Sawaya R., Kondo S., Kondo Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int. J. Oncol. 2007, 31:753-760.
153. Fava C., Morotti A., Dogliotti I., Saglio G., Rege-Cambrin G. Update on emerging treatments for chronic myeloid leukemia. Expert Opin. Emerg. Drugs 2015, 20:183-196.
154. Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future Oncol. 2015, 11:1327-1342.
155. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005, 65:9643-9650.
156. Al-Kzayer L.F., Sakashita K., Al-Jadiry M.F., Al-Hadad S.A., Uyen le T.N., Liu T., et al. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children. Pediatr. Blood Cancer 2014, 61:1980-1985.
157. Nakagawa T., Saitoh S., Imoto S., Itoh M., Tsutsumi M., Hikiji K., et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992, 49:114-122.
158. Yaktapour N., Ubelhart R., Schuler J., Aumann K., Dierks C., Burger M., et al. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood 2013, 122:1621-1633.
159. de la Puente P., Muz B., Azab F., Luderer M., Azab A.K. Molecularly targeted therapies in multiple myeloma. Leuk. Res. Treat. 2014, 2014:976567.
160. Bertacchini J., Heidari N., Mediani L., Capitani S., Shahjahani M., Ahmadzadeh A., et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol. Life Sci. 2015, 72:2337-2347.
161. Barrett D., Brown V.I., Grupp S.A., Teachey D.T. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 2012, 14:299-316.
162. Zhu J., Wang M., Cao B., Hou T., Mao X. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Curr. Med. Chem. 2014, 21:3173-3187.
163. Toulany M., Kasten-Pisula U., Brammer I., Wang S., Chen J., Dittmann K., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 2006, 12:4119-4126.
164. Raju U., Riesterer O., Wang Z.Q., Molkentine D.P., Molkentine J.M., Johnson F.M., et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother. Oncol. 2012, 105:241-249.
165. Myllynen L., Rieckmann T., Dahm-Daphi J., Kasten-Pisula U., Petersen C., Dikomey E., et al. In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother. Oncol. 2011, 101:147-151.
166. Toulany M., Lee K.J., Fattah K.R., Lin Y.F., Fehrenbacher B., Schaller M., et al. Akt1 promotes post-irradiation survival of human tumor cells through initiation, progression and termination of DNA-PKcs-dependent DNA-double strand break repair. Mol. Cancer Res. 2012, 10:945-957.
167. Fraser M., Harding S.M., Zhao H., Coackley C., Durocher D., Bristow R.G. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011, 10:2218-2232.
168. Khanna K.K., Jackson S.P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat. Genet. 2001, 27:247-254.
169. Iliakis G., Wang H., Perrault A.R., Boecker W., Rosidi B., Windhofer F., et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet. Genome Res. 2004, 104:14-20.
170. Hsu F.M., Zhang S., Chen B.P. Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Transl. Cancer Res. 2012, 1:22-34.
171. Bouchaert P., Guerif S., Debiais C., Irani J. Fromont G. DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84:1179-1185.
172. Povirk L.F., Zhou R.Z., Ramsden D.A., Lees-Miller S.P., Valerie K. Phosphorylation in the serine/threonine 2609-2647 cluster promotes but is not essential for DNA-dependent protein kinase-mediated nonhomologous end joining in human whole-cell extracts. Nucleic Acids Res. 2007, 35:3869-3878.
173. Douglas P., Sapkota G.P., Morrice N., Yu Y., Goodarzi A.A., Merkle D., et al. Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase. Biochem. J. 2002, 368:243-251.
174. Chen B.P., Chan D.W., Kobayashi J., Burma S., Asaithamby A., Morotomi-Yano K., et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J. Biol. Chem. 2005, 280:14709-14715.
175. Chen B.P., Uematsu N., Kobayashi J., Lerenthal Y., Krempler A., Yajima H., et al. Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break. J. Biol. Chem. 2007, 282:6582-6587.
176. Park J., Feng J., Li Y., Hammarsten O., Brazil D.P., Hemmings B.A. DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. J. Biol. Chem. 2009, 284:6169-6174.
177. Bozulic L., Surucu B., Hynx D., Hemmings B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 2008, 30:203-213.
178. Toulany M., Schickfluss T.A., Fattah K.R., Lee K.J., Chen B.P., Fehrenbacher B., et al. Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation. Radiother. Oncol. 2011, 101:140-146.
179. Mukherjee B., Choy H., Nirodi C., Burma S. Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: Rationale and strategies for radiosensitization. Semin. Radiat. Oncol. 2010, 20:250-257.
180. Meyn R.E. Linking PTEN with genomic instability and DNA repair. Cell Cycle 2009, 8:2322-2323.
181. Affolter A., Drigotas M., Fruth K., Schmidtmann I., Brochhausen C., Mann W.J., et al. Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer. Head Neck 2013, 35:220-228.
182. Lavin M.F. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 2007, 26:7749-7758.
183. Jeggo P.A., Geuting V., Lobrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother. Oncol. 2011, 101:7-12.
184. Goodarzi A.A., Jeggo P., Lobrich M. The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair 2010, 9:1273-1282.
185. Beucher A., Birraux J., Tchouandong L., Barton O., Shibata A., Conrad S., et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J. 2009, 28:3413-3427.
186. Viniegra J.G., Martinez N., Modirassari P., Losa J.H., Parada Cobo C., Lobo V.J., et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 2005, 280:4029-4036.
187. Khalil A., Morgan R.N., Adams B.R., Golding S.E., Dever S.M., Rosenberg E., et al. ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 2011, 10:481-491.
188. Hawkins A.J., Golding S.E., Khalil A., Valerie K. DNA double-strand break - Induced pro-survival signaling. Radiother. Oncol. 2011, 101:13-17.
189. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
190. Martin A.M., Blackwood M.A., Antin-Ozerkis D., Shih H.A., Calzone K., Colligon T.A., et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J. Clin. Oncol. 2001, 19:2247-2253.
191. Xiang T., Jia Y., Sherris D., Li S., Wang H., Lu D., et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 2011, 30:2443-2450.
192. Plo I., Laulier C., Gauthier L., Lebrun F., Calvo F., Lopez B.S. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res. 2008, 68:9404-9412.
193. Jia Y., Song W., Zhang F., Yan J., Yang Q. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene 2012, 32:1943-1949.
194. Puc J., Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005, 4:927-929.
195. Choi B.H., Chen Y., Dai W. Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation. Cell Cycle 2013, 12:3442-3447.
196. Li L., Wang H., Yang E.S., Arteaga C.L., Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008, 68:9141-9146.
197. Ciuffreda L., Di Sanza C., Cesta Incani U., Eramo A., Desideri M., Biagioni F., et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J. Mol. Med. (Berl.) 2012, 90:667-679.
198. Toulany M., Minjgee M., Saki M., Holler M., Meier F., Eicheler W., et al. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol. Ther. 2014, 15:317-328.
199. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
200. Richardson P.G., Wolf J., Jakubowiak A., Zonder J., Lonial S., Irwin D., et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J. Clin. Oncol. 2011, 29:4243-4249.
201. Figg W.D., Monga M., Headlee D., Shah A., Chau C.H., Peer C., et al. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemother. Pharmacol. 2014, 74:955-967.
202. Alonso-Basanta M., Fang P., Maity A., Hahn S.M., Lustig R.A., Dorsey J.F. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J. Neurooncol. 2014, 116:365-372.
203. Buijsen J., Lammering G., Jansen R.L., Beets G.L., Wals J., Sosef M., et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother. Oncol. 2013, 107:184-188.
204. Gonzalez-Angulo A.M., Krop I., Akcakanat A., Chen H., Liu S., Li Y., et al. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J. Natl. Cancer Inst. 2015, 107(3). Feb 16.
205. Brana I., Berger R., Golan T., Haluska P., Edenfield J., Fiorica J., et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br. J. Cancer 2014, 111:1932-1944.
206. Spencer A., Yoon S.S., Harrison S.J., Morris S.R., Smith D.A., Brigandi R.A., et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood 2014, 124:2190-2195.
207. Narayan R.S., Fedrigo C.A., Stalpers L.J., Baumert B.G., Sminia P. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr. Pharm. Des. 2013, 19:951-957.
208. Martini M., De Santis M.C., Braccini L., Gulluni F., Hirsch E. PI3K/AKT signaling pathway and cancer: An updated review. Ann. Med. 2014, 46:372-383.
209. Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front. Oncol. 2014, 4:64.
210. Pal I., Mandal M. PI3K and Akt as molecular targets for cancer therapy: Current clinical outcomes. Acta Pharmacol. Sin. 2012, 33:1441-1458.
211. Vink S.R., Schellens J.H., Beijnen J.H., Sindermann H., Engel J., Dubbelman R., et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol. 2006, 80:207-213.
212. Rengan R., Mick R., Pryma D., Rosen M.A., Lin L.L., Maity A.M., et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: A report of toxicities and clinical response. J. Thorac. Oncol. 2012, 7:709-715.
213. Brunner T.B., Geiger M., Grabenbauer G.G., Lang-Welzenbach M., Mantoni T.S., Cavallaro A., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 2008, 26:2699-2706.